Breaking News Instant updates and real-time market news.

AMAG

Amag Pharmaceuticals

$18.33

0.04 (0.22%)

06:28
11/06/18
11/06
06:28
11/06/18
06:28

JPMorgan downgrades Amag to Underweight on product uncertainties

JPMorgan analyst Jessica Fye downgraded Amag Pharmaceuticals to Underweight from Neutral and lowered her price target for the shares to $18 from $20. The analyst sees "uncertainties across multiple product lines" that she believes will lead the stock to underperform following Amag's Q3 results and preliminary negative 2019 profit view. Supply issues add a wrinkle in the Makena outlook, Fye tells investors in a research note. The analyst admits, however, that the company's ultimate 2019 financial results "may not be quite as bad as feared" and that the stock is "fairly washed out." Nonetheless, Fye views Amag as a "show me" story with 2019 set up as an investment year.

  • 27

    Nov

  • 23

    Mar

AMAG Amag Pharmaceuticals
$18.33

0.04 (0.22%)

11/06/18
JPMS
11/06/18
DOWNGRADE
Target $18
JPMS
Underweight
Amag Pharmaceuticals downgraded to Underweight from Neutral at JPMorgan
JPMorgan analyst Jessica Fye downgraded Amag Pharmaceuticals to Underweight and lowered her price target for the shares to $18 from $20. The analyst calls 2019 an investment year for the company.
11/02/18
PIPR
11/02/18
NO CHANGE
PIPR
Neutral
Amag's Makena supply issues 'more dire than thought,' says Piper Jaffray
Piper Jaffray analyst Christopher Raymond said that Amag Pharmaceuticals made what he would consider material additional disclosures in today's 10-Q filing that he did not hear during the company's earnings call yesterday regarding Makena supply disruptions. The company now states that Makena supply disruptions are expected to result in a stock-out of the multi-dose, 5mL vial "in the near future," which Raymond said is a change from last quarter's filing, which indicated supply limitations were confined to the single-dose, 1mL vial. The company also pointed to the potential for supply issues with Makena's SubQ auto-injector format, though that language "may be out of an abundance of caution," Raymond said. While he is not lowering his estimates, the filing details may indicate potential downside risk to Makena estimates, said the analyst, who keeps a Neutral rating on Amag shares.
11/01/18
PIPR
11/01/18
NO CHANGE
Target $20
PIPR
Neutral
Piper still cautious on Amag after 'bit of a bombshell' guidance
Piper Jaffray analyst Christopher Raymond lowered his price target for Amag Pharmaceuticals to $20 from $22 following the company's "essentially in-line" Q3 results and "surprisingly lower" initial fiscal 2019 guidance, he calls a "bit of a bombshell." The analyst is "flummoxed" by the non-GAAP EBITDA loss guidance of $50M, which he notes represents a $100M negative swing versus consensus. This appears to be driven by investment in Vyleesi, a product "in which we have very little confidence," Raymond tells investors in a post-earnings research note. He remains cautious on Amag shares with a Neutral rating.
09/26/18
PIPR
09/26/18
NO CHANGE
PIPR
Neutral
Piper says Amag goal to add 174 patients to trial by 2019 'may be a tall order'
Piper Jaffray analyst Christopher Raymond noted that Amag Pharmaceuticals announced it has taken over development of digoxin immune Fab for the treatment of severe preeclampsia from Velo Bio and seeks to add an additional 174 patients by the end of 2019, which he believes "may be a tall order." As he waits to see how enrollment progresses for this trial, he continues to have concerns with Amag's current franchise as Makena, which makes up over 70% of revenue, recently began facing generic competition, Raymond tells investors. The analyst maintains a Neutral rating on Amag shares and says he is still "comfortable on the sidelines."

TODAY'S FREE FLY STORIES

ADI

Analog Devices

$89.07

3.52 (4.11%)

12:50
11/20/18
11/20
12:50
11/20/18
12:50
Upgrade
Analog Devices rating change  »

Analog Devices upgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Nov

  • 26

    Nov

EA

Electronic Arts

$82.95

-0.09 (-0.11%)

, MSFT

Microsoft

$102.65

-1.97 (-1.88%)

12:48
11/20/18
11/20
12:48
11/20/18
12:48
OnTheFly
Game On: Nintendo, Microsoft still committed to E3 as Sony plans to skip »

Welcome to "Game On," The…

EA

Electronic Arts

$82.95

-0.09 (-0.11%)

MSFT

Microsoft

$102.65

-1.97 (-1.88%)

SNE

Sony

$49.86

-1.12 (-2.20%)

NTDOY

Nintendo

$0.00

(0.00%)

ATVI

Activision Blizzard

$49.80

0.63 (1.28%)

T

AT&T

$29.79

-0.55 (-1.81%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Nov

  • 26

    Nov

  • 28

    Nov

  • 03

    Dec

  • 04

    Dec

  • 05

    Dec

  • 03

    Mar

12:40
11/20/18
11/20
12:40
11/20/18
12:40
Options
Bearish spread in Invesco Senior Loan Portfolio as shares set 52-week lows »

Bearish spread in Invesco…

12:40
11/20/18
11/20
12:40
11/20/18
12:40
General news
Treasury Action: yields are mixed along the curve »

Treasury Action: yields…

NOK

Nokia

$5.58

-0.145 (-2.53%)

12:35
11/20/18
11/20
12:35
11/20/18
12:35
Options
Nokia put volume heavy and directionally bearish »

Bearish flow noted in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MSI

Motorola Solutions

$125.44

-0.82 (-0.65%)

12:27
11/20/18
11/20
12:27
11/20/18
12:27
Hot Stocks
Motorola Solutions wins second patent infringement suit against Hytera Mobilfunk »

Motorola Solutions…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Nov

  • 18

    Dec

  • 19

    Dec

CLF

Cleveland-Cliffs

$9.37

-0.6 (-6.02%)

12:25
11/20/18
11/20
12:25
11/20/18
12:25
Options
Cleveland-Cliffs call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MMAC

MMA Capital

$26.50

-0.2 (-0.75%)

12:25
11/20/18
11/20
12:25
11/20/18
12:25
Conference/Events
MMA Capital to host special shareholder meeting »

Special Shareholder…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Nov

SANW

S&W Seed

$3.05

(0.00%)

12:25
11/20/18
11/20
12:25
11/20/18
12:25
Conference/Events
S&W Seed to host special shareholder meeting »

Special shareholder…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Nov

12:25
11/20/18
11/20
12:25
11/20/18
12:25
Conference/Events
UBS alternative energy analyst to hold an analyst/industry conference call »

Alternative Energy…

TGT

Target

$69.29

-7.84 (-10.16%)

, BBY

Best Buy

$64.05

1.86 (2.99%)

12:19
11/20/18
11/20
12:19
11/20/18
12:19
OnTheFly
Fly Intel: Wall Street's top stories at midday »

Stocks opened in negative…

TGT

Target

$69.29

-7.84 (-10.16%)

BBY

Best Buy

$64.05

1.86 (2.99%)

CPB

Campbell Soup

$40.60

2.13 (5.54%)

KLIC

Kulicke & Soffa

$22.18

2.28 (11.46%)

A

Agilent

$67.54

4.97 (7.94%)

LIVN

LivaNova

$102.03

-18.25 (-15.17%)

LB

L Brands

$30.14

-4.39 (-12.71%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Nov

  • 20

    Nov

  • 20

    Nov

  • 20

    Nov

  • 20

    Nov

  • 27

    Nov

  • 05

    Dec

  • 11

    Dec

  • 03

    Mar

$NSD

NASDAQ Market Internals

$0.00

(0.00%)

12:17
11/20/18
11/20
12:17
11/20/18
12:17
Technical Analysis
NASDAQ market internals summary »

Volume is above average…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NYE

NYSE Market Internals

$0.00

(0.00%)

12:16
11/20/18
11/20
12:16
11/20/18
12:16
Technical Analysis
NYSE market internals summary »

Volume is above average…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BSX

Boston Scientific

$34.13

-1.16 (-3.29%)

12:10
11/20/18
11/20
12:10
11/20/18
12:10
Options
Puts lead calls 4:1 in Boston Scientific as implied volatilities lift »

Puts lead calls 4:1 in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Nov

  • 27

    Nov

12:10
11/20/18
11/20
12:10
11/20/18
12:10
General news
U.S. equities remain under pressure »

U.S. equities remain…

AMAT

Applied Materials

$36.27

1.85 (5.37%)

12:05
11/20/18
11/20
12:05
11/20/18
12:05
Options
Applied Materials call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

12:05
11/20/18
11/20
12:05
11/20/18
12:05
General news
FX Action: USD-CAD »

FX Action: USD-CAD…

FB

Facebook

$133.04

1.42 (1.08%)

12:02
11/20/18
11/20
12:02
11/20/18
12:02
Hot Stocks
Facebook experiencing service issues »

Visiting Facebook.com…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Nov

EGRX

Eagle Pharmaceuticals

$48.01

-1.36 (-2.75%)

12:01
11/20/18
11/20
12:01
11/20/18
12:01
Conference/Events
Eagle Pharmaceuticals management to meet with RBC Capital »

Group Dinner Meeting to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Nov

  • 27

    Nov

  • 02

    Dec

SDRL

Seadrill

$14.63

-1.84 (-11.17%)

12:00
11/20/18
11/20
12:00
11/20/18
12:00
Hot Stocks
Seadrill falls -11.2% »

Seadrill is down -11.2%,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

EROS

Eros International

$8.19

-1.16 (-12.41%)

12:00
11/20/18
11/20
12:00
11/20/18
12:00
Hot Stocks
Eros International falls -12.4% »

Eros International is…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 03

    Dec

  • 20

    Dec

LB

L Brands

$30.23

-4.3 (-12.45%)

12:00
11/20/18
11/20
12:00
11/20/18
12:00
Hot Stocks
L Brands falls -12.5% »

L Brands is down -12.5%,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Nov

SCO

Scor ADR

$23.44

2.26 (10.67%)

12:00
11/20/18
11/20
12:00
11/20/18
12:00
Hot Stocks
Scor ADR rises 10.9% »

Scor ADR is up 10.9%, or…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NOAH

Noah Holdings

$45.61

4.81 (11.79%)

12:00
11/20/18
11/20
12:00
11/20/18
12:00
Hot Stocks
Noah Holdings rises 11.3% »

Noah Holdings is up…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DWT

Britannia Bulk

$11.85

1.62 (15.84%)

12:00
11/20/18
11/20
12:00
11/20/18
12:00
Hot Stocks
Britannia Bulk rises 16.1% »

Britannia Bulk is up…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.